The table below shows Summit Therapeutics Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$322.93M
-$142.11M
-$76.76M
-$41.58M
-$72.59M
-$48.11M
Capital expenditure
$657.00K
$139.00K
$128.00K
$624.00K
$306.00K
$421.00K
Investing cash flow
-$174.31M
-$205.34M
-$587.77M
-$624.00K
-$306.00K
-$421.00K
Dividends paid
-
-
-
-
SMMT operating cash flow (10-K history)
Summit Therapeutics Inc. reported operating cash flow of -$322.93M for fiscal year 2025. That is down 127.2% from -$142.11M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$21.50M (FY 2018) to -$322.93M. Figures come from the company's audited annual reports as filed with the SEC.
